$BCRX This announcement was a bit of a surprise. Apparently management had this sNDA in the works in parallel while advancing the pediatric formulation. It looks like they were targeting three groups of patients: (1) new patients who want the convenience of a daily oral prophylaxis but have difficulty swallowing capsules, (2) existing O patients who struggle with capsules and (3) pediatric patients transitioning to adolescence who want to continue using the pellets. This may not seem like much but it is a positive achievement. If they can capture even a relatively small number of incremental patients from these three groups it could produce meaningful high-margin revenue over time. https://t.co/zOcH9SPZwv
View on X ↗